IQVIA Holdings Inc. (NYSE:IQV) Receives $224.13 Average Price Target from Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned an average rating of “Buy” from the seventeen ratings firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $224.1250.

IQV has been the subject of a number of recent analyst reports. Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday. HSBC set a $210.00 price objective on IQVIA in a research note on Wednesday, June 3rd. Royal Bank Of Canada initiated coverage on IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price objective for the company. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Finally, Morgan Stanley set a $225.00 target price on IQVIA in a research report on Thursday, May 7th.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $181.10 on Wednesday. The company has a market cap of $30.23 billion, a P/E ratio of 22.44, a PEG ratio of 1.56 and a beta of 1.21. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA has a one year low of $153.01 and a one year high of $247.04. The business’s 50-day simple moving average is $173.56 and its 200 day simple moving average is $193.44.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter last year, the firm earned $2.70 EPS. IQVIA’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts forecast that IQVIA will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has approved a stock repurchase program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA in the 4th quarter worth approximately $25,000. Financial Freedom LLC bought a new stake in shares of IQVIA in the 1st quarter worth approximately $25,000. Ascentis Independent Advisors bought a new stake in shares of IQVIA in the 1st quarter worth approximately $25,000. International Assets Investment Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth approximately $27,000. Finally, Gilpin Wealth Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth approximately $27,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.